当前位置: 首页 > 详情页

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China [2]Department of Neurology, The First Affiliated Hospital of Xi’an Jiaotong University, Xian, China [3]Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China [4]Department of Neurology, Xiangya Hospital Central South University, Changsha, China [5]Department of Neurology, The First Teaching Hospital of Jilin University, Changchun, China [6]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China [7]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China [8]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China
出处:
ISSN:

摘要:
The genetic risk effects of apolipoprotein E (APOE) on familial Alzheimer's disease (FAD) with or without gene mutations, sporadic AD (SAD), and normal controls (NC) remain unclear in the Chinese population. In total, 15 119 subjects, including 311 FAD patients without PSEN1, PSEN2, APP, TREM2, and SORL1 pathogenic mutations (FAD [unknown]); 126 FAD patients with PSENs/APP mutations (FAD [PSENs/APP]); 7234 SAD patients; and 7448 NC were enrolled. The risk effects of APOE ε4 were analyzed across groups. The prevalence of the APOE ε4 genotype in FAD (unknown), FAD (PSENs/APP), SAD, and NC groups was 56.27%, 26.19%, 36.23%, and 19.54%, respectively. Further, the APOE ε4 positive genotype had predictive power for FAD (unknown) risk (odds ratio: 4.51, 95% confidence interval: 3.57-5.45, P < .001). APOE ε4 positive genotype may cause familial aggregation, and the investigation of multiple interventions targeting APOE pathological function to reduce the risk for this disease warrants attention. © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 临床神经病学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 临床神经病学
JCR分区:
出版当年[2018]版:
Q1 CLINICAL NEUROLOGY
最新[2023]版:
Q1 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China
通讯作者:
通讯机构: [1]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China [6]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China [7]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China [8]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [*1]Innovation Center forNeurological Disorders and Department of Neurology, XuanwuHospital, Capital Medical University, National Clinical Research Center forGeriatric Diseases,Beijing 100053, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院